Renaissance Technologies LLC Has $2.50 Million Stock Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Renaissance Technologies LLC grew its stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 53.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 854,900 shares of the company’s stock after acquiring an additional 297,500 shares during the period. Renaissance Technologies LLC’s holdings in Poseida Therapeutics were worth $2,496,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Poseida Therapeutics by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in Poseida Therapeutics by 89.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after acquiring an additional 391,801 shares during the last quarter. Blair William & Co. IL grew its position in shares of Poseida Therapeutics by 41.3% in the 1st quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after acquiring an additional 282,310 shares during the period. Cantor Fitzgerald L. P. bought a new position in shares of Poseida Therapeutics in the 4th quarter valued at about $169,000. Finally, Public Employees Retirement System of Ohio increased its stake in shares of Poseida Therapeutics by 177.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock worth $201,000 after purchasing an additional 40,245 shares during the last quarter. Institutional investors and hedge funds own 46.87% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a research report on Tuesday, August 6th.

Poseida Therapeutics Stock Performance

Shares of Poseida Therapeutics stock opened at $2.75 on Wednesday. The company has a 50 day moving average of $3.06 and a 200-day moving average of $2.92. The company has a market cap of $266.63 million, a PE ratio of -2.31 and a beta of 0.51. The company has a current ratio of 2.48, a quick ratio of 2.48 and a debt-to-equity ratio of 0.97. Poseida Therapeutics, Inc. has a 1-year low of $1.83 and a 1-year high of $4.27.

Poseida Therapeutics (NASDAQ:PSTX) last posted its earnings results on Monday, August 5th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. The firm had revenue of $25.97 million during the quarter, compared to analysts’ expectations of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. As a group, equities research analysts forecast that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.